Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only._x000D_
_x000D_
#What CAGR Is Anticipated for the Cancer In Vitro Diagnostics (IVD) Market Through 2029?#_x000D_
In recent times, the cancer in vitro diagnostics (IVD) market has experienced robust growth. The market, which was worth $13.36 billion in 2024, is projected to increase to $14.32 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.2%. Factors contributing to this historic period of growth include an increase in research on cancer biomarkers, a surge in oncology trials needing testing, expanded government health programs, enhanced laboratory infrastructure support, and a rise in biotechnology funding._x000D_
_x000D_
Expectations for substantial expansion can be seen within the cancer in vitro diagnostics (IVD) market. The market is projected to escalate to a worth of $18.62 billion by 2029, courtesy of a compound annual growth rate (CAGR) of 6.8%. The impending growth over the forecast period is tied to factors such as state and NGO screening initiatives, an aging demographic, heightened awareness surrounding early cancer diagnosis, broadening of reimbursement coverage, and the rising prevalence of point-of-care (POC) diagnostics. Prevailing trends that can be seen for the forecast period incorporate the proliferation of liquid biopsy technologies, advancements within next-generation sequencing, application of artificial intelligence and machine learning, incorporation of microfluidics, and the integration of digital pathology._x000D_
_x000D_
#Download The Free Sample Report Here:#_x000D_
https://www.thebusinessresearchcompany.com/sample.aspx?id=27234&type=smp_x000D_
_x000D_
#What Market Forces Are Driving The Cancer In Vitro Diagnostics (IVD) Sector In 2025 And Beyond?#_x000D_
The rise in cancer occurrences is predicted to fuel the expansion of the cancer in vitro diagnostics (IVD) market in the future. Cancer is characterized by the unruly proliferation and dissemination of irregular cells within the body, which may infiltrate neighboring tissues and generate tumors. This surge in cancer incidences primarily stems from an ageing demographic, with a longer lifespan and decreased mortalities from infectious diseases leading to more older individuals at an elevated risk of cancer. In vitro diagnostics (IVD) for cancer serves an essential role by providing prompt and precise detection, surveillance, and control of cancer through lab tests on patients’ samples. This process aids in making quick treatment decisions and enhances patient outcomes. For example, as reported by the World Health Organization (WHO), an intergovernmental organization based in Switzerland, the total number of new cancer cases globally hit 20 million in 2022 and is forecast to escalate to 35 million by 2050, signifying a 77% hike. Consequently, the escalating rate of cancer is propelling the growth of the cancer in vitro diagnostics (IVD) market._x000D_
_x000D_
#How Is The Global Cancer In Vitro Diagnostics (IVD) Market Categorized By Segments?#_x000D_
The cancer in vitro diagnostics (IVD) market covered in this report is segmented_x000D_
_x000D_
1) By Product Type: Reagents And Kits, Instruments, Software And Services_x000D_
2) By Technology: Clinical Chemistry, Immunochemistry Or Immunoassays, Hematology, Coagulation And Hemostasis, Microbiology, Molecular Diagnostics, Other Technology _x000D_
3) By Cancer Type: Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer_x000D_
4) By End-Users: Hospitals, Laboratories, Academics, Point-Of-Care Testing, Patient Self-Testing, Other End Users_x000D_
_x000D_
Subsegments:_x000D_
1) By Reagents And Kits: PCR Reagents And Kits, NGS Reagents And Kits, Immunoassay Reagents And Kits, In Situ Hybridization (ISH) Reagents And Kits, Others_x000D_
2) By Instruments: PCR Instruments, NGS Instruments, Immunoassay Analyzers, ISH Instruments, Others_x000D_
3) By Software And Services: Data Analysis Software, Laboratory Information Management Systems, Cloud-Based Data Management, Instrument Integration Software, Support And Maintenance Services_x000D_
_x000D_
#What Long-Term Trends Are Likely To Affect The Cancer In Vitro Diagnostics (IVD) Market?#_x000D_
Major firms active in the cancer in vitro diagnostics (IVD) sector are centered on technological progress, like the CE in vitro diagnostic (IVD) cancer testing kits, to improve precision, accessibility, and standardization of genetic cancer tests across clinical environments. CE-in vitro diagnostic (IVD) cancer testing kits comply with the European Union’s in vitro diagnostic directive (IVDD) which ensures safety, validated efficiency, and top-tier quality for tests run on patients in European labs. In February 2022, for instance, Invitae, a genetics company based in the US, introduced the FusionPlex Dx and LiquidPlex Dx to Europe to bolster its oncology diagnostic offerings. FusionPlex Dx provides accurate detection of less frequent variations in FFPE samples for consistent clinical application. LiquidPlex Dx enables non-invasive cancer genomic profiling from blood, leading to fast results and the ability to capture tumor diversity. This makes it beneficial in personalized treatment and illness tracking when tissue samples are scarce._x000D_
_x000D_
#Which Firms Are Considered Leaders In The Cancer In Vitro Diagnostics (IVD) Market Space?#_x000D_
Major companies operating in the cancer in vitro diagnostics (IVD) market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, GE HealthCare Technologies Inc., Hologic Inc., Illumina Inc., bioMérieux SA, Sysmex Corporation, Exact Sciences Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Autobio Diagnostics Co Ltd., Transasia Bio-Medicals Ltd., NanoString Technologies Inc., Genetron Holdings Limited, Cancer Diagnostics Inc., J. Mitra & Co. Pvt Ltd., and Tulip Diagnostics (P) Ltd. _x000D_
_x000D_
#Get The Full Report Here:#_x000D_
_x000D_
#What Role Do Regional Policies And Investments Play In Cancer In Vitro Diagnostics (IVD) Market Expansion?#_x000D_
North America was the largest region in the cancer in vitro diagnostics (IVD) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer in vitro diagnostics (IVD) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_
_x000D_
#Request For A Customized Report:#_x000D_
https://www.thebusinessresearchcompany.com/customise?id=27234&type=smp_x000D_
_x000D_
#About The Business Research Company:#_x000D_
_x000D_
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_
_x000D_
#Get in touch with us:#_x000D_
_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas +1 310-496-7795_x000D_
Asia +44 7882 955267 & +91 8897263534_x000D_
Europe +44 7882 955267_x000D_
Email us at info@tbrc.info_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model